PEG-Liposomal Inhalation Formulation for Sustained Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhalable liposomal formulations are inadequate for treating pulmonary diseases like IPF, lacking stability, deep lung deposition, and effective drug retention, and oral tyrosine kinase inhibitors suffer from low bioavailability and severe side effects.
Innovation Solution
A liposomal sustained release composition comprising phospholipids, sterols, and PEG-modified phospholipids encapsulating tyrosine kinase inhibitors, designed for inhalation, with optimized particle size and lipid composition for enhanced stability and prolonged drug release in the lung.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral administration of tyrosine kinase inhibitor is used, then therapeutic effect is achieved, but bioavailability is very low and side effects are severe
Solution Approach 1:
The patent uses liposomes as intermediary carriers to deliver the tyrosine kinase inhibitor directly to the lung tissue. The liposomal formulation acts as a mediator between the drug and the target site, enabling direct pulmonary delivery and bypassing the gastrointestinal tract, thereby dramatically improving bioavailability from 4.7% to near 100% while reducing systemic side effects
Solution Approach 2:
The patent employs liposomal vesicles with flexible phospholipid bilayer membranes to encapsulate and protect the drug. These flexible shells allow the formulation to be aerosolized effectively and facilitate fusion with pulmonary cell membranes, enhancing drug uptake and cellular penetration while maintaining stability during inhalation delivery
2Ease of operation
If inhalable liposomal formulation is used, then direct drug delivery to lung is achieved, but stability and deep lung deposition are inadequate
Solution Approach 1:
The patent systematically optimized multiple formulation parameters including lipid composition (phospholipid to cholesterol ratio), particle size distribution (targeting 1-5 μm aerodynamic diameter), and surfactant content to achieve both stability and deep lung deposition. By adjusting these parameters, the formulation maintains structural integrity during storage and aerosolization while ensuring deep penetration into lung parenchyma
Solution Approach 2:
The patent creates a composite liposomal formulation combining multiple phospholipids, cholesterol, and co-surfactants in specific ratios. This composite material approach enhances formulation stability by creating a more robust vesicle structure that resists degradation during aerosolization and storage, while the optimized composition facilitates deep lung deposition and cellular uptake
3Reliability
If high dosage of oral tyrosine kinase inhibitor is administered, then therapeutic efficacy is improved, but side effects increase
Solution Approach 1:
The patent segments the drug delivery system into liposomal carriers that target specific lung tissue regions. This segmentation enables localized drug release at the disease site while minimizing systemic circulation, thereby maintaining therapeutic efficacy in the lung while reducing exposure of other organs to the drug and its associated side effects
Solution Approach 2:
The liposomal formulation serves as an intermediary that selectively delivers the drug to pulmonary tissue through aerosol inhalation. This mediator approach concentrates the therapeutic effect in the lung while limiting systemic absorption, achieving the desired therapeutic outcome with lower overall drug exposure and reduced side effects
4Reliability
If frequent dosing is implemented, then therapeutic effect is maintained, but patient compliance decreases
Solution Approach 1:
The patent designs the liposomal formulation to provide sustained and continuous drug release in the lung tissue. The controlled release mechanism maintains therapeutic drug concentrations over extended periods, eliminating the need for frequent dosing and thereby improving patient compliance while ensuring continuous therapeutic effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves therapeutic efficacy with lower doses, direct drug delivery to the disease site, reduced side effects, and increased bioavailability, allowing for less frequent dosing and improved patient outcomes.
Implementation Method 1
Liposomes are self-assembled, fatty acid vesicles composed of phospholipid bilayers with an aqueous interior
Implementation Method 2
amount of polyethylene glycol (PEG) on the liposome (to evade clearance by macrophage)
Implementation Method 3
High drug encapsulation inside a liposome can be achieved via a remote loading method (also known as active loading), which relies on transmembrane pH and ion gradients to allow for diffusion of free, uncharged drug molecules into the liposome
Implementation Method 4
A drug that has been stably entrapped in a liposome may be aerosolized or nebulized for inhalation delivery
Data Source
AI summary
Provided is a liposomal sustained-release composition for use in treatment of pulmonary disease. The liposomal sustained release composition comprises a liposome that includes a polyethylene glycol (PEG)-modified lipid and encapsulates a tyrosine kinase inhibitor. Tyrosine kinase inhibitor is stably entrapped in the liposome, and the resulting liposomal drug formulation can be aerosolized or nebulized for administration via inhalation. This aerosolized liposomal drug formulation yields consistent pharmacokinetic and pharmacodynamic profiles while achieving desired efficacy and safety.